Seeking Alpha

Henry McCusker's  Instablog

Henry McCusker
Send Message
Editor and Publisher ... Henry enters his thirteen (13) year at RegMed Investors which aggregates, curates and creates bottom-line content of regenerative medicine - stem, gene and cell therapy news providing a "vetted" selection of relevant and high-impact synthesis. He was VP -... More
My company:
Scimitar Equity-Regenerative Medicine Investors
My blog:
Scimitar Equity Blog
View Henry McCusker's Instablogs on:
  • Do We Need To Pause And Take A Breath?

    "Let's take another look at what's happening at Aastrom (ASTM). On Friday, we wrote … The evidence is somewhat ambiguous but, conjecture abounds …"

    < >

    … As some of the better names dropped on small volumes and "others" spiked to previously unseen levels such as Aastrom (ASTM) … I love it when one of our universe moves from earth to heaven. But … given the fact that they face a … $15 M offering; ASTM was UP +$0.155 or 35.63% to $0.59, someone needs to review the 3.871 M spike in volume and appreciation - but, where did the ASTM spike and resulting volume come from - it wasn't their status as a stable company?

    I am further … astounded by the volume momentum and the share price volatility … are shorts cover or has information leaked to the public? Who is saying … what to whom? The earning call on 8/8/13 should open many eyes and flap many an ear! However … with no news … the numbers do not add up and are not making sense so … many questions need to be answered.

    The Bottom Line: As of 10:30 a.m. 2.15 M shares of Aastrom have changed hands with the stock gaining +$0.13 <was $0.20> <+21.36%> to $0.719.

    Congratulations on a highly impressive, continuing run! But I am still … perplexed and frankly wonder why and/or what is the basis for this phenomena. There has been no news out of Aastrom since July 3, and that was only a generic announcement that the company was presenting at a conference.

    Quite frankly, such movement defies sound economics and investment logic. I am concerned that there may be an iceberg in the ship's charted course - being that somehow, surely on rumor, information is quietly entering the universe that needs vetting.

    Let them have their price run as many will scamper and sell from the "Icarus" heights … patience grasshopper? In the past has been paused by NASDAQ due to a 10% or more price move in the security in a five-minute period. My opinion!

    - See more at:

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Aug 05 12:13 PM | Link | Comment!
  • Northwest Bio (NWBO) Converts $11.6 M Debt To Cognate Bioservices

    Conversion Shares Also Subject To 18-Month Lock-Up Agreement

    (NWBO agreed to convert the $11.6 M of accounts payable to Cognate into shares of NW Bio common stock at a price of $4.00 per share. These conversions cover accounts payable from Q4 2012 through July of 2013.

    To assure that these shares will not be a factor in the market for an extended period of time, the NWBO and Cognate entered into a lock-up agreement to an 18-month lock-up of these conversion shares. On a going forward basis, NW Bio and Cognate agreed to establish a regular ongoing arrangement for payment of at least half of each invoice in stock, and the remainder in cash, at $4.00 per share. The arrangement will continue until terminated by mutual agreement.

    The Bottom Line: A good but, <inter-company> deal … for the balance sheet but, maybe not the dilutionary affect. Cognate has provided manufacturing and regulatory assistance to NW Bio in the US since 2004, in Israel since 2008 and in Europe since 2010. Interesting … Cognate shares common ownership with NW Bio (by Toucan Capital), and as such is an affiliate of NW Bio under the securities laws. NWBO reduces its cash burn while building its operations in Europe as well as the US; while pursuing 2 major clinical programs (both DCVax-L and DCVax-Direct) simultaneously.

    NWBO closed at $3.59 and is DOWN in the pre-market -$0.13 to $3.46. It will probably bottom-out at $3.25. NWBO had a float of 16.33 m shares and an outstanding share count of 30.1 M. I won't rate it with this event until it settles into a new-normal trading activity.

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

    Jul 31 9:09 AM | Link | Comment!
  • Cytori (CYTX) Divests Puregraft® Products, Licenses Celution® For Alopecia And Options Broader Aesthetic Market Rights

    $15 M - 3part agreement with Bimini Technologies and its affiliates, Puregraft Technologies and Kerastem Technologies

    CYTX has entered into a $15 M three-part agreement with Bimini Technologies and its affiliates, Puregraft Technologies and Kerastem Technologies.


    • CYTX has sold global manufacturing and commercialization rights for the Puregraft® product line. In exchange, CYTX has received a $5 M upfront payment and will receive up to an additional $10 M from commercial milestones related to future Puregraft® sales;
    • Bimini has acquired global, exclusive rights to commercialize the Celution® System for Alopecia (Hair Field). Under the commercial agreement, Bimini will be responsible for all clinical studies, regulatory approvals and market development activities for Alopecia and will pay CYTX perpetual royalties on sales;
    • Bimini has acquired an exclusive option to license Celution® products for the global aesthetics market. The option is effective until 12/31/13.

    The Bottom Line: This transaction enables Cytori to monetize a non-core product, Puregraft®, simultaneously increase operational focus on core Celution® cell therapeutic applications and market development, and establish a strategic partnership in the development of new market opportunities in Alopecia. Under this agreement, CYTX maintains certain limited rights to Puregraft® and the related technology and receives an exclusive license from Bimini for cell-enriched applications and future development activities (in exchange for royalty payments on Puregraft® from Cytori to Bimini), which in the aggregate, represent significant market opportunities for Cytori. Additionally, Bimini will continue negotiations to acquire market rights for the cell-based aesthetics market beyond Alopecia, which are actively underway.

    CYTX closed at $2.65 and has been in an up and down pricing spiral <$2.35 to $2.65> since 7/1/13 with moderate to high volume. CYTX is a … BUY at this price as this event should sway some momentum however, as we step toward earnings - - the pendulum always swings lower and jumps post LPS announcement.

    Puregraft® is an FDA-approved fat grafting product that allows patients to receive injections of their own fat in a single outpatient procedure. Cytori originally developed Puregraft® to be used in combination with its cell therapy technology. Given its simplicity and performance, Cytori has been offering Puregraft® as a stand-alone product to physicians in the U.S., Asia and Europe since 2010.

    Bimini is a newly formed company and is based in San Diego, California. Bradford Conlan, who has been part of the Cytori team for nearly 9 years developing and marketing both the Puregraft® and Celution® products, is the founding CEO of Bimini, as well as its affiliates Puregraft Technologies and Kerastem

    - See more at:

    Jul 31 8:29 AM | Link | Comment!
Full index of posts »
Latest Followers


  • ImmunoCellular (OTC BB: IMUC) files to Sell $13.8M of Units via Cowen
    Nov 30, 2011
  • Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
    Oct 26, 2011
More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.